The “Vaccine Research Market by End-user and Geography – Forecast and Analysis 2022-2026” report has been added to Technavio’s offering. The report expects the market size to grow by USD 13.34 billion, accelerating at a CAGR of 8.36% during the forecast period. According to the report, the market will observe high demand for vaccine research from the public end-user segment. Increased funding by governments across the world for the research and development of drugs for various diseases is creating high demand from this business segment. Our report on the vaccine research market provides a comprehensive analysis of the market behavior across various segments and regions. Download Sample PDF Report Now
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Novavax Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Takeda Pharmaceutical Co. Ltd. are some of the major market participants.
The market is driven by the high prevalence of infectious diseases, the need for novel vaccines for chronic infections, and a rise in the funding for the R&D of COVID-19 vaccines. To leverage the current opportunities, market vendors must strengthen their foothold in the fast-growing segments, while maintaining their positions in the slow-growing segments.
Vaccine Research Market 2022-2026: Segmentation
- End-user
- Public
- Private
The public segment accounted for the largest share of the market in 2021. There are various government organizations that are involved in the research of vaccines, such as the US National Institute of Allergy and Infectious Diseases (NIAID) and the US National Institutes of Health (NIH). Following the outbreak of the highly deadly COVID-19 pandemic in early 2020 and its rapid spread across the world, countries scrambled to develop effective vaccines to counter the new and extremely virulent SARS-CoV-2 virus. Such efforts are fostering the growth of the segment.
- Geography
- North America
- Europe
- Asia
- Rest Of World (ROW)
North America will emerge as a major market, occupying 42% of the global market share. The strong prevalence of infectious diseases, such as influenza, hepatitis A, hepatitis B, HIV, measles, malaria, and tuberculosis, and non-infectious diseases such as cancer is driving the growth of the regional market.
Get deeper insights into the contribution of each business segment and region toward the growth of the global market by purchasing our full report. Start by Downloading a Free SampleVaccine research Market 2022-2026: Vendor Analysis and Scope
To help businesses improve their market position, the vaccine research market provides a detailed analysis of around 25 vendors operating in the market. Some of these vendors include:
- Bavarian Nordic AS: The company is involved in vaccine research for diseases such as smallpox, respiratory syncytial virus, SARS CoV2 and immuno oncology. Some of the pipeline products are ABNCOV2, MVA BN freeze dried, MVA BN RSV, and TAEK VAC.
- CSL Ltd.: The company is involved in vaccine research for the disease influenza namely Flucelvax.
- Emergent BioSolutions Inc.: The company is involved in vaccine research for diseases such as chikungunya virus, influenza, lassa fever, and marburg virus. Some of the pipeline products are AV7909, CHIKV VLP, UniFlu, WEVEE VLP, and EBS Lassa.
- GlaxoSmithKline Plc: The company is involved in vaccine research for diseases such as measles, mumps, rubella prophylaxis, rotavirus prophylaxis, and COVID-19. Some of the pipeline products are Rotarix, MMR, Menveo, and Xevudy.
- Inovio Pharmaceuticals Inc.: The company is involved in vaccine research for diseases such as Covid 19, HPV associated disease, immuno oncology. Some of the pipeline products are INO 4800, VGX 3100, and INO 4500.
- Abbott Laboratories
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bharat Biotech Ltd.
- CanSino Biologics Inc.
- Daiichi Sankyo Co. Ltd.
- Johnson and Johnson
- Merck and Co. Inc.
- Mitsubishi Chemical Holdings Corp.
- Novavax Inc.
- Panacea Biotec Ltd.
- Pfizer Inc.
- Sanofi
- Serum Institute of India Pvt. Ltd.
- Takeda Pharmaceutical Co. Ltd.
Vaccine research Market 2022-2026: Key Highlights
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist vaccine research market growth during the next five years
- Estimation of the vaccine research market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the vaccine research market
- Analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of vaccine research market vendors
Related Reports:
- Human Vaccine Market by Route of Administration and Geography – Forecast and Analysis 2022-2026
- Vaccine Adjuvants Market by Application and Geography – Forecast and Analysis 2020-2024
| Vaccine Research Market Scope | |
| Report Coverage | Details |
| Page number | 120 |
| Base year | 2021 |
| Forecast period | 2022-2026 |
| Growth momentum & CAGR | Accelerate at a CAGR of 8.36% |
| Market growth 2022-2026 | USD 13.34 billion |
| Market structure | Fragmented |
| YoY growth (%) | 7.15 |
| Regional analysis | North America, Europe, Asia, and Rest of World (ROW) |
| Performing market contribution | North America at 42% |
| Key consumer countries | US, Canada, UK, Germany, and China |
| Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
| Companies profiled | Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Novavax Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Takeda Pharmaceutical Co. Ltd. |
| Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of contents:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis – Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition – Five forces 2021 and 2026
5 Market Segmentation by End-user
- 5.1 Market segments
- Exhibit 24: Chart on End-user – Market share 2021-2026 (%)
- Exhibit 25: Data Table on End-user – Market share 2021-2026 (%)
- 5.2 Comparison by End-user
- Exhibit 26: Chart on Comparison by End-user
- Exhibit 27: Data Table on Comparison by End-user
- 5.3 Public – Market size and forecast 2021-2026
- Exhibit 28: Chart on Public – Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Public – Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Public – Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Public – Year-over-year growth 2021-2026 (%)
- 5.4 Private – Market size and forecast 2021-2026
- Exhibit 32: Chart on Private – Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Private – Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Private – Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Private – Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by End-user
- Exhibit 36: Market opportunity by End-user ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America – Market size and forecast 2021-2026
- Exhibit 42: Chart on North America – Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America – Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America – Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America – Year-over-year growth 2021-2026 (%)
- 7.4 Europe – Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe – Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Europe – Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Europe – Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe – Year-over-year growth 2021-2026 (%)
- 7.5 Asia – Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia – Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Asia – Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Asia – Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia – Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) – Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
- 7.7 US – Market size and forecast 2021-2026
- Exhibit 58: Chart on US – Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US – Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US – Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US – Year-over-year growth 2021-2026 (%)
- 7.8 UK – Market size and forecast 2021-2026
- Exhibit 62: Chart on UK – Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on UK – Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on UK – Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on UK – Year-over-year growth 2021-2026 (%)
- 7.9 Germany – Market size and forecast 2021-2026
- Exhibit 66: Chart on Germany – Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Germany – Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Germany – Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Germany – Year-over-year growth 2021-2026 (%)
- 7.10 Canada – Market size and forecast 2021-2026
- Exhibit 70: Chart on Canada – Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on Canada – Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on Canada – Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Canada – Year-over-year growth 2021-2026 (%)
- 7.11 China – Market size and forecast 2021-2026
- Exhibit 74: Chart on China – Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on China – Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on China – Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on China – Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 Bavarian Nordic AS
- Exhibit 85: Bavarian Nordic AS – Overview
- Exhibit 86: Bavarian Nordic AS – Product / Service
- Exhibit 87: Bavarian Nordic AS – Key news
- Exhibit 88: Bavarian Nordic AS – Key offerings
- 10.4 CSL Ltd.
- Exhibit 89: CSL Ltd. – Overview
- Exhibit 90: CSL Ltd. – Business segments
- Exhibit 91: CSL Ltd. – Key news
- Exhibit 92: CSL Ltd. – Key offerings
- Exhibit 93: CSL Ltd. – Segment focus
- 10.5 Emergent BioSolutions Inc.
- Exhibit 94: Emergent BioSolutions Inc. – Overview
- Exhibit 95: Emergent BioSolutions Inc. – Product / Service
- Exhibit 96: Emergent BioSolutions Inc. – Key news
- Exhibit 97: Emergent BioSolutions Inc. – Key offerings
- 10.6 GlaxoSmithKline Plc
- Exhibit 98: GlaxoSmithKline Plc – Overview
- Exhibit 99: GlaxoSmithKline Plc – Business segments
- Exhibit 100: GlaxoSmithKline Plc – Key news
- Exhibit 101: GlaxoSmithKline Plc – Key offerings
- Exhibit 102: GlaxoSmithKline Plc – Segment focus
- 10.7 Inovio Pharmaceuticals Inc.
- Exhibit 103: Inovio Pharmaceuticals Inc. – Overview
- Exhibit 104: Inovio Pharmaceuticals Inc. – Product / Service
- Exhibit 105: Inovio Pharmaceuticals Inc. – Key offerings
- 10.8 Johnson and Johnson
- Exhibit 106: Johnson and Johnson – Overview
- Exhibit 107: Johnson and Johnson – Business segments
- Exhibit 108: Johnson and Johnson – Key news
- Exhibit 109: Johnson and Johnson – Key offerings
- Exhibit 110: Johnson and Johnson – Segment focus
- 10.9 Merck and Co. Inc.
- Exhibit 111: Merck and Co. Inc. – Overview
- Exhibit 112: Merck and Co. Inc. – Business segments
- Exhibit 113: Merck and Co. Inc. – Key news
- Exhibit 114: Merck and Co. Inc. – Key offerings
- Exhibit 115: Merck and Co. Inc. – Segment focus
- 10.10 Novavax Inc.
- Exhibit 116: Novavax Inc. – Overview
- Exhibit 117: Novavax Inc. – Product / Service
- Exhibit 118: Novavax Inc. – Key offerings
- 10.11 Pfizer Inc.
- Exhibit 119: Pfizer Inc. – Overview
- Exhibit 120: Pfizer Inc. – Product / Service
- Exhibit 121: Pfizer Inc. – Key news
- Exhibit 122: Pfizer Inc. – Key offerings
- 10.12 Sanofi
- Exhibit 123: Sanofi – Overview
- Exhibit 124: Sanofi – Business segments
- Exhibit 125: Sanofi – Key news
- Exhibit 126: Sanofi – Key offerings
- Exhibit 127: Sanofi – Segment focus
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 128: Inclusions checklist
- Exhibit 129: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 130: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 131: Research methodology
- Exhibit 132: Validation techniques employed for market sizing
- Exhibit 133: Information sources
- 11.5 List of abbreviations
- Exhibit 134: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio